Myocardial infarction (MI) is a leading cause of death globally and is characterized by extensive cardiomyocyte death, fibrosis, and diminished cardiac function, leading to heart failure. The limited regenerative capacity and excessive fibrosis of the heart highlight the need for effective therapeutic strategies. The Notch signaling pathway, known for its role in cell fate determination and tissue repair, is transiently activated after MI in cardiomyocytes, endothelial cells, and smooth muscle cells. This activation modulates cardiac repair by reducing oxidative stress and apoptosis, regulating inflammation, promoting angiogenesis, and inhibiting fibrosis. Recent research has focused on targeting the Notch pathway to increase myocardial regeneration and angiogenesis via the use of gene therapy, small-molecule regulators, and cell-based therapies. For example, delivering Notch ligands through hydrogels has yielded promising results in preclinical studies, enhancing cardiac function and promoting angiogenesis. This review examines the molecular mechanisms by which Notch signaling influences cardiac repair post-MI. We also discuss its specific roles in cardiomyocyte regeneration, fibrosis inhibition, and angiogenesis enhancement. Additionally, this study evaluated the therapeutic potential of Notch pathway modulation, addressing clinical translation challenges, safety concerns, and the importance of personalized treatment strategies. Future research directions include leveraging gene editing and nanotechnology-based drug delivery to improve the efficacy and safety of Notch-targeted therapies for cardiovascular diseases.
Endometriosis is a chronic inflammatory disease characterized by immune microenvironment dysregulation, with the IL-33/ST2L signaling axis playing a crucial role in macrophage polarization and disease progression. Despite growing evidence of IL-33's involvement in endometriosis pathogenesis, the mechanisms underlying IL-33-induced macrophage polarization and the therapeutic potential of a natural immunomodulator luteolin remain incompletely understood. We investigated the effects of luteolin on IL-33/ST2L-mediated M2 macrophage polarization using in vitro cell culture models and an in vivo mouse endometriosis model. The proliferation and migration of human endometrial stromal cells (HESCs) were assessed following macrophage co-culture experiments. The MyD88/NF-κB signaling pathway and inflammatory cytokine expression were analyzed using Western blotting, RT-PCR, and ELISA. IL-33 significantly promoted M2 macrophage polarization, which subsequently enhanced HESC proliferation and migration. Luteolin treatment effectively suppressed IL-33/ST2L signaling, inhibited IL-33-induced M2 macrophage polarization, and reduced HESC proliferative and migratory activities. In the mouse endometriosis model, luteolin administration decreased IL-33 secretion, prevented M2 macrophage accumulation, and downregulated the MyD88/NF-κB pathway. This resulted in significant reduction of pro-inflammatory cytokines (IL-1β, TNF-α, IL-4, and IL-13) and amelioration of the local immune microenvironment. Our findings demonstrate that luteolin exerts therapeutic effects in endometriosis by disrupting IL-33/ST2L-mediated M2 macrophage polarization and modulating inflammatory responses. These results suggest that luteolin is a promising natural therapeutic candidate for endometriosis treatment, offering insights into immune-targeted therapeutic strategies.
21 May 2026 in Biochemical and Biophysical Research Communications